UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) (State or other j ...

Dave Rosa - CEO Ron McClurg - CFO Ladies and gentlemen, thank you for standing by, and welcome to the NeuroOne Medical Technologies Corporation Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results Conference Call. With that said, I'll turn the call over to Dave Rosa, CEO of NeuroOne. Dave? So first and foremost, thanks for joining us this evening. During our fiscal fourth quarter and through today, the Company continued to make significant strides in our objectives relating to commercial progre ...

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q3 2023 Results Conference Call August 14, 2023 4:30 PM ET Dave Rosa - Chief Executive Officer Ron McClurg - Chief Financial Officer Good day, ladies and gentlemen. Thank you for standing by. And welcome to the NeuroOne Medical Technologies Corporation Third Quarter Fiscal Year 2023 Financial Results Conference Call. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa; and the Chief Financial Officer, Ron McClurg. With th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27-0 ...

Thank you, Dave. Product revenue was $466,000 in the fiscal second quarter of 2023 compared to product revenue of just $37,000 in last year's second quarter. In the first six months of fiscal 2023, Product revenue was $581,000 compared to $70,000 for the same period in fiscal 2022. Collaboration revenue was $1.46 million in the first six months of fiscal 2023 and compared to collaboration revenue of $6,000 in the first six months of fiscal 2022. Sure. Yes. And the full -- it will be the full sales force. Ob ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware 27- ...

Dave Rosa - President and CEO Ron McClurg - CFO Ladies and gentlemen, thank you for standing by. And welcome to the NeuroOne Medical Technologies Corporation First Quarter Fiscal Year 2023 Financial Results Conference Call. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa; and Chief Financial Officer, Ron McClurg. Thanks, operator, and thanks everyone for your attendance today. Now I'll discuss our efforts in developing electrodes that could be used for chronic stimulation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware ...

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q4 2022 Results Conference Call December 13, 2022 4:30 PM ET Company Participants Dave Rosa - President and Chief Executive Officer Ron McClurg - Chief Financial Officer Operator Ladies and gentlemen, thank you for standing by. And welcome to the NeuroOne Medical Technologies Corporation Corporate Update Conference Call. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa; and Chief Financial Officer, Ron McClurg. Before ...

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q3 2022 Earnings Conference Call August 11, 2022 5:30 PM ET Company Participants Dave Rosa - President and Chief Executive Officer Ron McClurg - Chief Financial Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital Group Ben Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. And welcome to the NeuroOne Medical Technologies Corporation Third Quarter of Fiscal Year 2022 Financial Results Conf ...